医学
随机对照试验
芬戈莫德
内科学
临床终点
复发-缓解
多发性硬化
观察研究
干扰素β-1a
比率
置信区间
免疫学
干扰素β
作者
Alessio Signori,Marta Ponzano,Tomáš Kalinčík,Serkan Özakbaş,Dana Horáková,Eva Havrdová,Raed Alroughani,Francesco Patti,Jens Kühle,Guillermo Izquierdo,Sara Eichau,Bassem Yamout,Samia J. Khoury,Rana Karabudak,Pierre Grammond,Pierre Duquette,Izanne Roos,Helmut Butzkueven,Anneke van der Walt,Maria Pia Sormani
标识
DOI:10.1136/jnnp-2023-332603
摘要
To mimic as closely as possible a randomised controlled trial (RCT) and calibrate the real-world evidence (RWE) studies against a known treatment effect would be helpful to understand if RWE can support causal conclusions in selected circumstances. The aim was to emulate the TRANSFORMS trial comparing Fingolimod (FTY) versus intramuscular interferon β-1a (IFN) using observational data.
科研通智能强力驱动
Strongly Powered by AbleSci AI